{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T20:31:18Z","timestamp":1785357078118,"version":"3.55.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.taap.2025.117426","type":"journal-article","created":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T10:57:35Z","timestamp":1749293855000},"page":"117426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["In silico cardiac safety profile of drugs and their potential to induce clinical cardiotoxicity"],"prefix":"10.1016","volume":"502","author":[{"given":"Bernard","family":"Christophe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2025.117426_bb0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1476-5381.2011.01378.x","article-title":"hERG subunit composition determines differential drug sensitivity","volume":"164","author":"Abi-Gerges","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2025.117426_bb0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1472-8206.1994.tb00818.x","article-title":"In vitro electrophysiological detection of iatrogenic arrhythmogenicity","volume":"8","author":"Adamantidis","year":"1994","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.taap.2025.117426_bb0015","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/europace\/euaa111","article-title":"Repolarization instability and arrhythmia by IKr block in single human-induced pluripotent stem cell-derived cardiomyocytes and 2D monolayers","volume":"22","author":"Altrocchi","year":"2020","journal-title":"Europace"},{"key":"10.1016\/j.taap.2025.117426_bb0020","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.vascn.2016.12.003","article-title":"A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes","volume":"84","author":"Ando","year":"2017","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0025","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fphys.2020.00314","article-title":"Simulation of the effects of extracellular calcium changes leads to a novel computational model of human ventricular action potential with a revised calcium handling","volume":"11","author":"Bartolucci","year":"2020","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2025.117426_bb0030","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/bjp.2008.215","article-title":"Moving towards better predictors of drug-induced torsades de pointes","volume":"154","author":"Bass","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2025.117426_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2021.107114","article-title":"Use of automated patch clamp in cardiac safety assessment: past, present & future perspectives","volume":"111","author":"Bell","year":"2021","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2020.01.010","article-title":"Multi-scale approaches for the simulation of cardiac electrophysiology: II - tissue-level structure and function","volume":"185","author":"Benson","year":"2021","journal-title":"Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3389\/fphys.2017.00597","article-title":"Quantitative comparison of effects of Dofetilide, Sotalol, quinidine, and verapamil between human ex vivo trabeculae and in silico ventricular models incorporating inter-individual action potential variability","volume":"8","author":"Britton","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2025.117426_bb0050","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fphys.2017.00278","article-title":"The Electrogenic Na(+)\/K(+) pump is a key determinant of repolarization abnormality susceptibility in human ventricular cardiomyocytes: a population-based simulation study","volume":"8","author":"Britton","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2025.117426_bb0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1159\/000257528","article-title":"Tissue slices from adult mammalian hearts as a model for pharmacological drug testing","volume":"24","author":"Bussek","year":"2009","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.taap.2025.117426_bb0060","first-page":"745","article-title":"Comprehensive in vitro Proarrhythmia assay, a novel in vitro\/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative","volume":"13","author":"Cavero","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.taap.2025.117426_bb0065","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.vascn.2016.05.012","article-title":"Comprehensive in vitro Proarrhythmia assay (CiPA): pending issues for successful validation and implementation","volume":"81","author":"Cavero","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0070","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3389\/fphys.2017.00917","article-title":"Uncertainty quantification reveals the importance of data variability and experimental design considerations for in silico Proarrhythmia risk assessment","volume":"8","author":"Chang","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.taap.2025.117426_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70098","article-title":"An overview of drug-induced sodium channel blockade and changes in cardiac conduction: implications for drug safety","volume":"17","author":"Chaudhary","year":"2024","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.taap.2025.117426_bb0080","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S1734-1140(13)71486-5","article-title":"Simulation of early after-depolarisation in non-failing human ventricular myocytes: can this help cardiac safety pharmacology?","volume":"65","author":"Christophe","year":"2013","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.taap.2025.117426_bb0085","first-page":"88","article-title":"In silico study of transmural dispersion of repolarization in non-failing human ventricular myocytes: contribution to cardiac safety pharmacology","volume":"7","author":"Christophe","year":"2015","journal-title":"J. Pharmaceut. Res. Int."},{"key":"10.1016\/j.taap.2025.117426_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2022.115914","article-title":"Occurrence of early afterdepolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: in silico study using 109 torsadogenic or non-torsadogenic compounds","volume":"438","author":"Christophe","year":"2022","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.taap.2025.117426_bb0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2018.12.004","article-title":"Impact of disease state on arrhythmic event detection by action potential modelling in cardiac safety pharmacology","volume":"96","author":"Christophe","year":"2019","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vascn.2016.06.002","article-title":"The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - update on progress","volume":"81","author":"Colatsky","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0105","first-page":"3001","article-title":"Arrhythmic risk biomarkers for the assessment of drug cardiotoxicity: from experiments to computer simulations","volume":"368","author":"Corrias","year":"2010","journal-title":"Philos. Trans. A Math. Phys. Eng. Sci."},{"key":"10.1016\/j.taap.2025.117426_bb0110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/01.RES.41.4.415","article-title":"Action potentials, afterpotentials, and arrhythmias","volume":"41","author":"Cranefield","year":"1977","journal-title":"Circ. Res."},{"key":"10.1016\/j.taap.2025.117426_bb0115","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0125","first-page":"263","article-title":"La tachycardie ventriculaire \u00e0 deux foyers oppos\u00e9s variables","volume":"59","author":"Dessertenne","year":"1966","journal-title":"Archive des. Maladies du Coeur."},{"key":"10.1016\/j.taap.2025.117426_bb0130","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pbiomolbio.2017.02.007","article-title":"Electrophysiological properties of computational human ventricular cell action potential models under acute ischemic conditions","volume":"129","author":"Dutta","year":"2017","journal-title":"Prog. Biophys. Mol. Biol."},{"key":"10.1016\/j.taap.2025.117426_bb0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.vascn.2014.09.005","article-title":"Human stem cell-derived cardiomyocytes detect drug-mediated changes in action potentials and ion currents","volume":"70","author":"Gibson","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0140","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/toxsci\/kft113","article-title":"Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays","volume":"134","author":"Harris","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.taap.2025.117426_bb0145","doi-asserted-by":"crossref","first-page":"R90027","DOI":"10.7554\/eLife.90027.3","article-title":"Assessing drug safety by identifying the axis of arrhythmia in cardiomyocyte electrophysiology","volume":"12","author":"Heitmann","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.taap.2025.117426_bb0150","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1254\/jphs.11038FP","article-title":"Electrophysiological characterization of cardiomyocytes derived from human induced pluripotent stem cells","volume":"117","author":"Honda","year":"2011","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.taap.2025.117426_bb0155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1540-8167.2006.00347.x","article-title":"Thorough QT\/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs","volume":"17","author":"Hondeghem","year":"2006","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.taap.2025.117426_bb0160","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.hrthm.2008.05.006","article-title":"QT prolongation is an unreliable predictor of ventricular arrhythmia","volume":"5","author":"Hondeghem","year":"2008","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.taap.2025.117426_bb0165","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40264-017-0584-4","article-title":"Drug-induced QT prolongation and Torsades de pointes: an all-exclusive relationship or time for an amicable separation?","volume":"41","author":"Hondeghem","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.taap.2025.117426_bb0170","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00210-010-0549-y","article-title":"Oscillations of cardiac wave length and proarrhythmia","volume":"382","author":"Hondeghem","year":"2010","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.taap.2025.117426_bb0175","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCULATIONAHA.105.550111","article-title":"Restricting excessive cardiac action potential and QT prolongation: a vital role for IKs in human ventricular muscle","volume":"112","author":"Jost","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.taap.2025.117426_bb0180","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1113\/jphysiol.2013.261198","article-title":"Ionic mechanisms limiting cardiac repolarization reserve in humans compared to dogs","volume":"591","author":"Jost","year":"2013","journal-title":"J. Physiol."},{"key":"10.1016\/j.taap.2025.117426_bb0185","first-page":"1","article-title":"Bifurcation theory and cardiac arrhythmias","volume":"3","author":"Karagueuzian","year":"2013","journal-title":"Am. J. Cardiovasc. Dis."},{"key":"10.1016\/j.taap.2025.117426_bb0190","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/srep02100","article-title":"MICE models: superior to the HERG model in predicting torsade de pointes","volume":"3","author":"Kramer","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2025.117426_bb0195","doi-asserted-by":"crossref","first-page":"H106","DOI":"10.1152\/ajpheart.00115.2016","article-title":"Dynamical mechanisms of phase-2 early afterdepolarizations in human ventricular myocytes: insights from bifurcation analyses of two mathematical models","volume":"312","author":"Kurata","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.taap.2025.117426_bb0200","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.vascn.2005.04.011","article-title":"Nonclinical proarrhythmia models: predicting Torsades de pointes","volume":"52","author":"Lawrence","year":"2005","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0205","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4196\/kjpp.2012.16.5.327","article-title":"Wide spectrum of inhibitory effects of sertraline on cardiac ion channels","volume":"16","author":"Lee","year":"2012","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"10.1016\/j.taap.2025.117426_bb0210","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.117.006035","article-title":"Human induced pluripotent stem cell-derived engineered heart tissue as a sensitive test system for QT prolongation and arrhythmic triggers","volume":"11","author":"Lemoine","year":"2018","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"10.1016\/j.taap.2025.117426_bb0220","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/cpt.1184","article-title":"Assessment of an in silico mechanistic model for Proarrhythmia risk prediction under the CiPA initiative","volume":"105","author":"Li","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2025.117426_bb0225","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jcim.0c00201","article-title":"In silico classifiers for the assessment of drug Proarrhythmicity","volume":"60","author":"Llopis-Lorente","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.taap.2025.117426_bb0230","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.vascn.2005.04.007","article-title":"Choice of cardiac tissue plays an important role in the evaluation of drug-induced prolongation of the QT interval in vitro in rabbit","volume":"52","author":"Lu","year":"2005","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0235","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jelectrocard.2017.08.011","article-title":"Cardiologist\u2019s point of view: novel ECG biomarkers and in silico models for proarrhythmic risk prediction: are we ready?","volume":"50","author":"Mason","year":"2017","journal-title":"J. Electrocardiol."},{"key":"10.1016\/j.taap.2025.117426_bb0240","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1039\/C7TX00141J","article-title":"Early afterdepolarisation tendency as a simulated pro-arrhythmic risk indicator","volume":"6","author":"McMillan","year":"2017","journal-title":"Toxicol. Res. (Camb)"},{"key":"10.1016\/j.taap.2025.117426_bb0245","series-title":"Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays","first-page":"1","article-title":"Computational cardiac safety testing","author":"Mirams","year":"2022"},{"key":"10.1016\/j.taap.2025.117426_bb0250","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1749-6632.2011.06324.x","article-title":"Is it time for in silico simulation of drug cardiac side effects?","volume":"1245","author":"Mirams","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.taap.2025.117426_bb0255","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cvr\/cvr044","article-title":"Simulation of multiple ion channel block provides improved early prediction of compounds\u2019 clinical torsadogenic risk","volume":"91","author":"Mirams","year":"2011","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2025.117426_bb0260","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.vascn.2014.07.002","article-title":"Prediction of thorough QT study results using action potential simulations based on ion channel screens","volume":"70","author":"Mirams","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0265","doi-asserted-by":"crossref","first-page":"17623","DOI":"10.1038\/srep17623","article-title":"Quantitative profiling of the effects of Vanoxerine on human cardiac ion channels and its application to cardiac risk","volume":"5","author":"Obejero-Paz","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2025.117426_bb0270","article-title":"Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation","volume":"7","author":"O\u2019Hara","year":"2011","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.taap.2025.117426_bb0275","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1400142","article-title":"Screening system for drug-induced arrhythmogenic risk combining a patch clamp and heart simulator","volume":"1","author":"Okada","year":"2015","journal-title":"Sci. Adv."},{"key":"10.1016\/j.taap.2025.117426_bb0280","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.vascn.2016.05.016","article-title":"Human ex-vivo action potential model for pro-arrhythmia risk assessment","volume":"81","author":"Page","year":"2016","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.taap.2025.117426_bb0285","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1111\/bph.14786","article-title":"Drug-induced shortening of the electromechanical window is an effective biomarker for in silico prediction of clinical risk of arrhythmias","volume":"176","author":"Passini","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2025.117426_bb0290","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.hrthm.2009.07.002","article-title":"Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org)","volume":"6","author":"Postema","year":"2009","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.taap.2025.117426_bb0295","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cvr\/cvt104","article-title":"Early afterdepolarizations in cardiac myocytes: beyond reduced repolarization reserve","volume":"99","author":"Qu","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2025.117426_bb0300","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2025.117426_bb0305","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1021\/acs.jcim.7b00440","article-title":"In silico QT and APD prolongation assay for early screening of drug-induced Proarrhythmic risk","volume":"58","author":"Romero","year":"2018","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.taap.2025.117426_bb0310","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1749-6632.1984.tb20776.x","article-title":"The clinical relevance of afterdepolarizations","volume":"427","author":"Rosen","year":"1984","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.taap.2025.117426_bb0315","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ahj.2013.11.004","article-title":"Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the cardiac safety research consortium","volume":"167","author":"Sager","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.taap.2025.117426_bb0320","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.309","article-title":"Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug","volume":"5","author":"Schlit","year":"2017","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.taap.2025.117426_bb0325","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.hrthm.2005.03.023","article-title":"Refining detection of drug-induced proarrhythmia: QT interval and TRIaD","volume":"2","author":"Shah","year":"2005","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.taap.2025.117426_bb0330","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and Proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.taap.2025.117426_bb0335","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48890","article-title":"Development, calibration, and validation of a novel human ventricular myocyte model in health, disease, and drug block","volume":"8","author":"Tomek","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.taap.2025.117426_bb0340","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevLett.102.258103","article-title":"Bifurcation and chaos in a model of cardiac early afterdepolarizations","volume":"102","author":"Tran","year":"2009","journal-title":"Phys. Rev. Lett."},{"key":"10.1016\/j.taap.2025.117426_bb0345","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1152\/physrev.00017.2023","article-title":"Computational modeling of cardiac electrophysiology and arrhythmogenesis: toward clinical translation","volume":"104","author":"Trayanova","year":"2024","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.taap.2025.117426_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.08.010","article-title":"Pharmacological enhancement of repolarization reserve in human induced pluripotent stem cells derived cardiomyocytes","volume":"169","author":"Treat","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.taap.2025.117426_bb0355","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2024.1363848","article-title":"Mechanisms of torsades de pointes: an update","volume":"11","author":"Tsuji","year":"2024","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.taap.2025.117426_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/biom12030459","article-title":"Bifurcations and Proarrhythmic behaviors in cardiac electrical excitations","volume":"12","author":"Tsumoto","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.taap.2025.117426_bb0365","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1152\/physrev.00024.2019","article-title":"Cardiac transmembrane ion channels and action potentials: cellular physiology and arrhythmogenic behavior","volume":"101","author":"Varr\u00f3","year":"2021","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.taap.2025.117426_bb0370","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/j.1476-5381.2009.00116.x","article-title":"Self-augmentation of the lengthening of repolarization is related to the shape of the cardiac action potential: implications for reverse rate dependency","volume":"156","author":"Vir\u00e1g","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.taap.2025.117426_bb0375","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.hrthm.2010.09.017","article-title":"Early afterdepolarizations and cardiac arrhythmias","volume":"7","author":"Weiss","year":"2010","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.taap.2025.117426_bb0380","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/cvr\/cvt006","article-title":"The new antiarrhythmic drug vernakalant: ex vivo study of human atrial tissue from sinus rhythm and chronic atrial fibrillation","volume":"98","author":"Wettwer","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.taap.2025.117426_bb0385","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/00005344-199711000-00006","article-title":"Rate-independent effects of the new class III antiarrhythmic agent ambasilide on transmembrane action potentials in human ventricular endomyocardium","volume":"30","author":"Weyerbrock","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.taap.2025.117426_bb0390","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.210235","article-title":"Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine","volume":"8","author":"Whittaker","year":"2021","journal-title":"R. Soc. Open Sci."},{"key":"10.1016\/j.taap.2025.117426_bb0395","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.drudis.2016.09.027","article-title":"Am I or am I not proarrhythmic? Comparison of various classifications of drug TdP propensity","volume":"22","author":"Wi\u015bniowska","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.taap.2025.117426_bb0400","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tcm.2017.07.010","article-title":"CredibleMeds.org: what does it offer?","volume":"28","author":"Woosley","year":"2018","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.taap.2025.117426_bb0405","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jphs.2018.02.005","article-title":"Proarrhythmia risk prediction using human induced pluripotent stem cell-derived cardiomyocytes","volume":"136","author":"Yamazaki","year":"2018","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.taap.2025.117426_bb0410","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart"},{"key":"10.1016\/j.taap.2025.117426_bb0415","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3389\/fphar.2019.01643","article-title":"Blinded in silico drug trial reveals the minimum set of ion channels for Torsades de pointes risk assessment","volume":"10","author":"Zhou","year":"2019","journal-title":"Front. Pharmacol."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X25002029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X25002029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:27:52Z","timestamp":1753205272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X25002029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":81,"alternative-id":["S0041008X25002029"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2025.117426","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico cardiac safety profile of drugs and their potential to induce clinical cardiotoxicity","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2025.117426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117426"}}